India's MRNA COVID-19 Vaccine Candidate Nears Finish Line

[email protected]19 Oct, 2021News

India-based Gennova Biopharmaceuticals Ltd. confirmed it had been granted authorization to conduct phase 2/3 clinical trials for the mRNA-based COVID-19 vaccine candidate HGCO19. Gennova submitted the proposed Phase II and Phase III study entitled ?A Prospective, Multicentre, Randomized, Active-controlled, Observer-blind, Phase II study seamlessly followed by a Phase III study to evaluate safety and tolerability, and immunogenicity of the vaccine candidate HGCO19 in healthy subjects."